Global Lung Cancer Therapeutics Market Reaches $37.5 Billion in 2024, Expanding at a 10.3% CAGR

The global lung cancer therapeutics market was valued at $37,500 million in 2024 and is growing at a CAGR of 10.3% during the forecast period (2026-2035). Regulatory validation of next-generation immunotherapies is increasing physician confidence and shifting the market from traditional chemotherapy to immune-based treatments, thereby accelerating the adoption of advanced immunotherapy for advanced small-cell lung cancer. This trend is evidenced by recent regulatory actions supporting novel immunotherapies. For instance, in November 2025, FDA granted full approval to the immunotherapy drug tarlatamab (Imdelltra) for adults with advanced small-cell lung cancer (SCLC) that has spread after platinum-based chemotherapy. Tarlatamab functions as a bispecific T cell engager, linking tumor cells to T cells to enhance the immune response against cancer. In a study of 509 patients, those treated with tarlatamab exhibited a 40% reduction in death risk compared to standard chemotherapy, even among patients with extensive disease spread, where the five-year survival rate is typically below 10%.

Browse the full report description of “Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report by Cancer Type (Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC)), by Therapy Type (Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, and Others), and by End User (Hospitals, Cancer Research Institutes, Specialty Clinics, and Homecare Settings) Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/lung-cancer-therapeutics-market

Leading Forces Shaping Innovation in Lung Cancer Therapeutics

The key players in the lung cancer therapeutics market include AstraZeneca PLC, Boehringer Ingelheim International GmbH., Bristol-Myers Squibb Co., Novartis AG, Eli Lilly and Co., among others. These companies are driving innovation in digital health solutions, including telemedicine, electronic health records, remote patient monitoring, and AI-powered clinical tools, thereby shaping the future of healthcare delivery globally.

• In October 2025, the FDA approved the combination of Roche’s Tecentriq (atezolizumab) and lurbinectedin (Zepzelca) as the first-line maintenance therapy for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after initial treatment. This is the first therapy of its kind for maintenance treatment of ES-SCLC, an aggressive cancer with previously limited options. The regimen has been endorsed in the updated NCCN Guidelines as a category 2A preferred maintenance treatment after induction therapy with Tecentriq and carboplatin/etoposide.
• In November 2025, FDA approved sevabertinib, the first cancer drug developed based on Broad Institute discoveries. Created by Bayer Healthcare, it is an oral treatment for non-small-cell lung cancer, specifically for adults with certain HER2 mutations who have previously undergone chemotherapy or immunotherapy. An estimated 4,000 to 8,000 patients in the US, many of whom are women, could benefit each year. The approval follows a Phase I/II clinical trial showing over 70% of patients had significant tumor shrinkage or disappearance.

Market Coverage

• The market number available for – 2024-2035
• Base year- 2024
• Forecast period- 2025-2035
• Segment Covered-
  • By Cancer Type
  • By Therapy Type
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - AstraZeneca PLC, Boehringer Ingelheim International GmbH., Bristol-Myers Squibb Co., Novartis AG, Eli Lilly and Co., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Lung Cancer Therapeutics Market Report Segment

By Cancer Type

• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

By Therapy Type

• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Radiation Therapy
• Others (Combination Therapy, And Adjuvant/ Neoadjuvant Therapy)

By End User

• Hospitals
• Cancer Research Institutes
• Specialty Clinics
• Homecare Settings

Global Lung Cancer Therapeutics Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/lung-cancer-therapeutics-market